This single-center study utilizes real-world data (2012-2024) from 4700 renal cell carcinoma (RCC) patients at Peking University Third Hospital to: (1) Develop and validate a prognostic prediction model specifically for RCC patients, including those with venous tumor thrombus (VTT); (2) Compare the performance of this new model against existing RCC prediction models in both the overall RCC cohort and the VTT subgroup; (3) Employ an emulated target trial (ETT) methodology to evaluate whether risk-stratified treatment based on the prediction model (grouping patients as high/medium/low risk) improves survival outcomes .
Adults ≥18 years of age;
Diagnosis of primary renal cell carcinoma before and during the surgery;
Received radical nephrectomy/nephron-sparing surgery.
Subjects with severely missing clinical information;
History of other malignant tumors.
Recurrence observed before first postoperative follow-up.
Discontinue the adjuvant treatment within in the first two course because of severe adverse react.
The groups of cohort will be selected from inhospital patients in Peking University Third Hospital.
Cohort
Other
Model-guided adjuvant treatment
Procedure/SurgeryInitiation of standard adjuvant treatment within 12 weeks after surgery.
No adjuvant treatment
Procedure/SurgeryNo initiation of adjuvant ICIs, radiotherapy, or targeted therapy at any point during follow-up prior to disease progression.
Disease-free Survival
The duration from the date of diagnosis to death or last follow-up, with no restriction on the cause of death.
Click on the lead sponsor to view all of their trials.
